---

VP of Application Science, BioPharmics Division, Optibrium

A 3D molecular design, predictive pharmacology, and lead discovery/optimization expert, Ann focuses on the challenges of complex macrocyclic ligand optimization, an increasingly important area of drug discovery because of the potential of macrocycles against previously “undruggable” targets. She has collaborated with many pharmaceutical and agrochemical organizations to improve 3D design. By exposing the bias towards making new molecules that look like existing molecules in two dimensions, Ann hopes to shift the mindset of drug designers into three dimensions. 

“A natural consequence of meeting with such seemingly diverse groups is that the groups learn each other's contributions to the project. In fact, those individuals who see the whole picture tend to matriculate to leadership positions. This has been a constant in my experience.”